NCT01081353已完成1 期
An Open Label 4-Way Crossover Pharmacokinetic Trial of New Formula Aspirin Versus Effervescent Aspirin in Healthy Adult Subjects
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- Bayer
- 入组人数
- 26
- 主要终点
- Bioavailability of new formulation aspirin versus marketed effervescent tablets (500mg aspirin)
研究概览
简要总结
To determine the bioequivalence of new formula of aspirin relative to the established commercial effervescent aspirin when taken orally by healthy adult subjects
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 55 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Healthy male and female subjects between 18 to 55 years of age inclusive with a Body Mass Index (BMI) of approximately 18 to 30 kg/m2; and a total body weight >50 kg (110 lbs)
- •Results of screening and clinical laboratory tests are within normal range or considered not clinically significant by the Principal Investigator or Sponsor
- •Female subjects of childbearing potential must be using a medically acceptable form of birth control for at least 1 month prior to screening (3 months on oral contraceptives), e.g., oral or patch contraceptives, intrauterine device, Depo-Provera, or a double barrier and have a negative pregnancy test at Screening and Day 0 for each Dosing Period. Female subjects of non-childbearing potential must be amenorrheic for at least 2 years or had a hysterectomy and/or bilateral oophorectomy
- •Be willing to participate in all scheduled visits, treatment plan, laboratory tests and other trial procedures according to the clinical protocol
排除标准
- •History of hypersensitivity to aspirin (ASA), Nonsteroidal Antiinflammatory Drugs (NSAIDs), acetaminophen and similar pharmacological agents or components of the products
- •Eighteen to twenty year olds with a viral infection, with or without fever, at the time of dosing - Syndromes of asthma, rhinitis or nasal polyps
- •Females who are pregnant or lactating
- •Have taken ASA, ASA-containing products, acetaminophen or any other NSAID (Over the counter (OTC) or prescription) 7 days prior to dosing or during the treatment period, other than trial treatment
- •Smokers or currently consuming any type of tobacco product(s) including any smoking cessation nicotine-containing product (e.g., nicotine patch, nicotine gum)
研究组 & 干预措施
Arm 4
Active Comparator
干预措施: Aspirin Aspro (Drug)
Arm 1
Experimental
干预措施: Acetylsalicylic Acid (Aspirin BAY1019036) (Drug)
Arm 2
Active Comparator
干预措施: Alka Seltzer Extra Strength (Drug)
Arm 3
Active Comparator
干预措施: Aspirin Migraine (Drug)
结局指标
主要结局
Bioavailability of new formulation aspirin versus marketed effervescent tablets (500mg aspirin)
时间窗: 24 hours
次要结局
- Adverse event collection(24 hours)
研究者
相似试验
已完成
1 期
Pharmacokinetic Study Comparing Aspirin and Aspirin GranulesPharmacokineticsNCT01072604Bayer30
已完成
1 期
Pharmacokinetics (PK) and Pharmacodynamics (PD) of Mayne Glucagon for Injection Compared With Glucagen® (Novo Nordisk) in Healthy VolunteersHypoglycemiaNCT00745186Hospira, now a wholly owned subsidiary of Pfizer28
招募中
不适用
Comparative Pharmacodynamics and Pharmacodynamics Equivalence of Antareit 800 mg/10 ml Oral Suspension and Riopan 800 mg Chewable Tablets in Healthy VolunteersHeartburnAcid-dependent Diseases of the Gastrointestinal TractSymptomatic Treatment of Gastric and Duodenal UlcersNCT06098742Valenta Pharm JSC50
已完成
不适用
Comparative Pharmacodynamics and Pharmacodynamics Equivalence of Antareit 800 mg Chewable Tablets and Riopan 800 mg Chewable Tablets in Healthy VolunteersHeartburnAcid-dependent Diseases of the Gastrointestinal TractSymptomatic Treatment of Gastric and Duodenal UlcersNCT06552624Valenta Pharm JSC40
已完成
1 期
Crossover Study to Compare Pharmacokinetic Property of SYP-1512 Tab and Revlimid Cap in Healthy Male VolunteersHealthy, MaleNCT03208218Samyang Biopharmaceuticals Corporation42